Toggle Main Menu Toggle Search

Open Access padlockePrints

Poly(ADP-ribose) polymerase (PARP) and PARP inhibitors

Lookup NU author(s): Professor Nicola CurtinORCiD


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


PARP-1 protects cells from endogenous and therapeutically inflicted DNA damage. PARP inhibitors have been under development since 1980 and first entered clinical trial in 2003. They are an exciting new class of drugs that have the potential to increase the efficacy of anticancer DNA damaging agents and to selectively target cells that have defects in other DNA repair pathways. There are now nine PARP inhibitors undergoing clinical evaluation

Publication metadata

Author(s): Curtin NJ

Publication type: Article

Publication status: Published

Journal: Drug Discovery Today: Disease Models

Year: 2012

Volume: 9

Issue: 2

Pages: e51-e58

Print publication date: 11/02/2012

ISSN (electronic): 1740-6757

Publisher: Elsevier Ltd


DOI: 10.1016/j.ddmod.2012.01.004


Altmetrics provided by Altmetric